|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 14.2 1.85 11.53%
Vice President Head of Project and Portfolio Management
Ms. Cecilia Forberg serves as Vice President Head of Project and Portfolio Management at Swedish Orphan Biovitrum AB. She joined the Company in 2001. She joined Kabi Pharmacia in 1989 and has held various project management positions primarily within biopharmaceutical process development in Kabi Pharmacia Pharmacia and Pharmacia Upjohn. She holds a MS degree in Chemical Engineering and Doctorate of Philosophy degree in Biochemical Engineering from the Royal Institute of Technology in Stockholm .
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 8.0 %
which means that it generated profit of $8.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 5.6 %
meaning that it generated $5.6 on every $100 dollars invested by stockholders.
The company has accumulated 53.55 M in total debt with debt to equity ratio (D/E) of 0.09 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.74 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.